semaglutide

40 · 20 / page

Ask MedXY AI

Latest news

Tag

Cardiologycardiovascular outcomesGLP-1 receptor agonists

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

By MedXY|Jan 4, 2026

A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight re

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

Cardiologycardiovascular diseasehospitalization

semaglutide

Latest news

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution